Stifel Reiterates $45 PT on Fulcrum Therapeutics (FULC) on Attractive Risk/Reward
Tweet Send to a Friend
Stifel analyst Dae Gon Ha reiterated a Buy rating and $45.00 price target on Fulcrum Therapeutics (NASDAQ: FULC) on the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
